dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Londoño, María-Carlota |
dc.contributor.author | Riveiro Barciela, Maria del Mar |
dc.contributor.author | Ahumada, Adriana |
dc.contributor.author | Muñoz-Gómez, Raquel |
dc.contributor.author | Roget, Mercé |
dc.contributor.author | Devesa-Medina, María J. |
dc.date.accessioned | 2020-08-03T09:34:17Z |
dc.date.available | 2020-08-03T09:34:17Z |
dc.date.issued | 2019-09-24 |
dc.identifier.citation | Londoño MC, Riveiro-Barciela M, Ahumada A, Muñoz-Gómez R, Roget M, Devesa-Medina MJ, et al. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in spanish clinical practice – Vie-KinD study. PLoS One. 2019 Sep 24;14(9):e0221567. |
dc.identifier.issn | 1932-6203 |
dc.identifier.uri | https://hdl.handle.net/11351/5132 |
dc.description | Coinfecció VIH i Hepatitis C; Insuficiència Renal Crònica; Ribavirina |
dc.description.sponsorship | MCL has served as consultant for AbbVie, MSD, Janssen, BMS and Gilead; MRB has received grant research from Gilead Science, and speaker fees from AbbVie, Gilead and MSD; MR has received speaker fees from AbbVie; MD has received grant support and consultancy fees from AbbVie, Bayer, Bristol-Myers Squibb, Gilead and Merck, Sharp & Dhome; FGR has served as speaker for AbbVie, Gilead and BMS; MLM has served as a speaker for AbbVie, BMS, Gilead, Janssen, MSD and ViiV; as a consultant for AbbVie, BMS and Janssen and has received research funding from FIPSE 36465/03, FIPSE 36680/07.-NEAT IG5 (NEAT is a project funded by the European Union under the 6th Framework programme) contract number LSHP-CT-2006-037570; MAC has served as a consultant for Gilead and and ViiV healthcare, and has received speaker fees from Janssens, Gilead, ViiV Healthcare; MMA reports personal fees from ViiV Healthcare, Gilead Sciences, Merck, Janssen, AbbVie and ABBOTT Laboratories, outside the submitted work; AR has received consultancy and speaker fees from AbbVie, Gilead Sciences and Merck Sharp & Dohme; JM has received honoraria, speaker fees, consultant fees or funds for research from AbbVie, BMS, Boehringer-Ingelheim, Gilead, Janssen, MSD, Roche and ViiV; EGP has received speaker fees from AbbVie and Gilead; LGB has served as consultant for AbbVie and Intercept and has received speaker fees from Gilead and MSD; AA, RMG, CB, TAE, MLG, BPL, IC, SB, LB, JGS, MJP, IMG, LM, IdlS, ML and JEL don't have a financial interest or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this paper; CdA and AM are paid employees of AbbVie and may hold stock or options. The specific roles of these authors are articulated in the 'author contributions' section. The design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the manuscript. |
dc.language.iso | eng |
dc.publisher | Public Library of Science |
dc.relation.ispartofseries | PLoS One;14(9) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Infeccions per VIH - Tractament |
dc.subject | Hepatitis C - Tractament |
dc.subject.mesh | Coinfection |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Hepatitis C, Chronic |
dc.subject.mesh | HIV Infections |
dc.title | Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in spanish clinical practice – Vie-KinD study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1371/journal.pone.0221567 |
dc.subject.decs | coinfección |
dc.subject.decs | /tratamiento farmacológico |
dc.subject.decs | hepatitis C crónica |
dc.subject.decs | infecciones por VIH |
dc.relation.publishversion | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0221567 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Londoño MC] Liver Unit, Hospital Clínic/IDIBAPS, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERhed), Instituto de Salud Carlos III, Madrid, Spain. [Riveiro-Barciela M] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERhed), Instituto de Salud Carlos III, Madrid, Spain. Servei de Medicina Interna, Unitat de Malalties Hepàtiques, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Ahumada A] Department of Gastroenterology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Muñoz-Gómez R] Department of Gastroenterology, Hospital General Universitario 12 de Octubre, Madrid, Spain. [Roget M] Liver Unit, Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain. [Devesa-Medina MJ] Department of Gastroenterology, Hospital Universitario Clínico San Carlos, Madrid, Spain |
dc.identifier.pmid | 31550267 |
dc.identifier.wos | 000532307700007 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |